key: cord-0745589-n1qlyjeq
authors: Shehab, Mohammad; Alrashed, Fatema; Shuaibi, Sameera; Alajmi, Dhuha; Barkun, Alan
title: Gastroenterological and hepatic manifestations of patients with COVID-19, prevalence, mortality by country, and intensive care admission rate: systematic review and meta-analysis
date: 2021-03-04
journal: BMJ Open Gastroenterol
DOI: 10.1136/bmjgast-2020-000571
sha: e1c87238be03fbd0dcb1ad4eec06f6dceb1f128a
doc_id: 745589
cord_uid: n1qlyjeq

BACKGROUND AND AIMS: Patients infected with the SARS-CoV-2 usually report fever and respiratory symptoms. However, multiple gastrointestinal (GI) manifestations such as diarrhoea and abdominal pain have been described. The aim of this study was to evaluate the prevalence of GI symptoms, elevated liver enzymes and mortality of patients with COVID-19. METHODS: A systematic review and meta-analysis of published studies that included a cohort of patients infected with SARS-CoV-2 were performed from 1 December 2019 to 15 December 2020. Data were collected by conducting a literature search using PubMed, Embase, Scopus, and Cochrane according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We analysed pooled data on the prevalence of individual GI symptoms and elevated liver enzymes and performed subanalyses to investigate the relationship between GI symptoms/elevated liver enzymes, geographical location, mortality, and intensive care unit (ICU) admission. RESULTS: The available data of 78 798 patients positive for SARS-CoV-2 from 158 studies were included in our analysis. The most frequent manifestations were diarrhoea (16.5%, 95% CI 14.2% to 18.4%), nausea (9.7%, 95% CI 9.0% to 13.2%) and elevated liver enzymes (5.6%, 95% CI 4.2% to 9.1%). The overall mortality and GI mortality were 23.5% (95% CI 21.2% to 26.1%) and 3.5% (95% CI 3.1% to 6.2%), respectively. Subgroup analysis showed non-statistically significant associations between GI symptoms/elevated liver enzymes and ICU admissions (OR=1.01, 95% CI 0.55 to 1.83). The GI mortality was 0.9% (95% CI 0.5% to 2.2%) in China and 10.8% (95% CI 7.8% to 11.3%) in the USA. CONCLUSION: GI symptoms/elevated liver enzymes are common in patients with COVID-19. Our subanalyses showed that the presence of GI symptoms/elevated liver enzymes does not appear to affect mortality or ICU admission rate. Furthermore, the proportion of GI mortality among patients infected with SARS-CoV-2 varied based on geographical location.

In December 2019, China was faced with a new strain of coronavirus, novel coronavirus (2019 nCov). Within a short period of time, it manifested into a full pandemic. 1 It was first noticed by the innumerable cases of pneumonia that suddenly surged among local inhabitants in the province of Wuhan. 2 Soon, the virus was detected through sequencing, leading to it officially being renamed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses. 3 The disease caused by SARS-CoV-2 was allocated the title of COVID-19 or 'coronavirus disease'. 3 Coronaviruses in general are single-stranded RNA viruses falling under the family of Coronaviridae, which also include Middle East respiratory syndrome coronavirus (MERS Cov) and SARS (SARS-CoV). 4 By the end of December 2020, more than 81 million cases of COVID-19 have officially been confirmed worldwide, and mortality from COVID-19 was more than 1 798 050 deaths worldwide. 5 In addition, new variants of SARS-CoV-2 have been discovered in the UK, South Africa, and other regions around the world. 6 It has been established that the transmission of SARS-CoV-2 occurs from person to person through the upper airway tract (droplet infection) or through direct contact. 7 The virus can also be detected in saliva, urine, gastrointestinal (GI) tract and possibly through airborne spread. 8 9 The spectrum of symptoms attributable to SARS-CoV-2 includes fever, cough, myalgia, fatigue, and, to a lesser extent, headache. Patients may also be asymptomatic. [10] [11] [12] Diarrhoea, nausea and vomiting, as well as liver involvement have all been Open access reported in the literature. 13 14 In fact, GI involvement is plausible, given that ACE2, the major human cellular receptor for the SARS-CoV-2, is expressed in the GI tract, as well as in liver cells. 15 We thus conducted a systematic review of published GI symptoms and elevated liver enzymes associated with COVID-19 on the basis of disease severity, mortality, intensive care unit (ICU) admission, and geographical region. This will aid in understanding the magnitude of involvement of the GI tract and liver in patients with COVID-19.

A systematic review was conducted using PubMed, Scopus, Cochrane, and Embase databases. Medical literature searches for human studies were performed from 1 December 2019 up to 15 December 2020. The key terms used for the literature search were (("COVID-19" OR "COVID 2019" OR "severe acute respiratory syndrome coronavirus 2" OR "severe acute respiratory syndrome coronavirus 2" OR "2019 nCoV" OR "SARS-COV2" OR "2019nCoV" OR ("severe acute respiratory syndrome coronavirus 2" OR "SARS-COV2" AND "gastrointestinal" AND ("manifestations" OR "clinical characteristics") OR ("gastrointestinal tract" OR ("gastrointestinal' AND "tract") OR "gastrointestinal tract" OR ("gi" AND "tract") OR ("fatality" or "Mortality"). In addition, a manual search of all review articles, editorials and retrieved original studies was also performed. All procedures used in this meta-analysis were consistent with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and prespecified protocol, which described our method and analysis before data collection was initiated (see online supplemental material PRISMA checklist).

Data were independently extracted by two investigators (MS and FA) and any discrepancies between the two authors were resolved through discussion. Inclusion and exclusion criteria were defined prior to the literature search. The inclusion criteria were (1) study type: case reports/case series (including chart reviews), prospective/retrospective cohort studies, case-control studies, cross-sectional studies and randomised controlled trials;

(2) patient population: adult patients with COVID-19, inpatient or outpatient setting; and (3) outcome measured: at least one reported GI symptom or elevated liver enzyme, number of patients admitted to ICU, and number of deaths reported. In addition, systematic reviews and meta-analyses were also reviewed for any relevant studies.

For the purpose of this study, elevated liver enzyme defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value above the upper limit of normal of each study laboratory reference range. Furthermore, overall mortality was defined as the proportion of deaths among identified confirmed COVID-19 cases in all studies that reported it. The number of deaths among patients experiencing GI symptoms/elevated liver enzymes was extracted and referred to as GI mortality.

Exclusion criteria were (1) review, opinion, abstracts from conferences, editorials, commentary articles, and review articles; (2) studies without data for retrieval; (3) duplicate studies; (4) asymptomatic patients with COVID-19; and (5) studies that did not report GI symptoms.

Data extraction was performed using Microsoft Excel. The following data were extracted: 1. Study 

The Methodical Index for Non-randomized Studies (MINORS) 16 was used to assess bias risk. In addition, risk of bias was assessed based on four domains: selection, ascertainment, causality, and reporting. An overall judgement of risk of bias was made based on factors deemed to be most critical for the systematic review (selection criteria, ascertainment of outcome, and follow-up duration).

Our primary analysis focused on assessing the weighted pooled prevalence of GI symptoms/elevated liver enzymes in patients with COVID-19 infection, occurring any time during the course of illness. We also conducted subanalyses that looked at the association between GI symptoms/elevated liver enzymes and mortality as well as ICU admission. Categorical variables were described as count (%). Continuous variables were described using mean (SD) if they are normally distributed, median (IQR) if they are not. We pooled the single-arm event rates using a random effects method, and we measured heterogeneity within our studies using the I 2 statistic. Subanalyses were described and tested using ORs and 95% CIs to determine statistical significance. STATA V.16 was used to calculate ORs and their respective 95% CI and to create Forest and box plots.

To examine the effect of the quality of studies on our results, we performed a sensitivity analysis on the prevalence of GI symptoms/elevated liver enzymes by excluding low-quality studies. To do so, we used the modified Newcastle-Ottawa Quality Assessment Scale for non-randomised studies. 17 A study with a score of 0-3

was classified as a low-quality study. On the other hand, studies that scored 4 or above were included in the analysis.

Overall, 158 studies (online supplemental table 1) from 3175 potentially relevant citations were included in the analysis (figure 1). Most of the included studies were single arm only; very few studies included comparator groups. Furthermore, outcome assessors in all 158 studies were not blinded. Both inpatient and outpatient studies were included. The risk of evidence imprecision was rated as very serious, given that the included studies were all observational studies. Overall, all included studies were rated as having very serious risk of bias because they lacked a control group and had a high risk of confounding and selection bias (online supplemental 

The sensitivity analysis included 52 studies (online supplemental tables 4 and 5). The results did not differ from our main analysis. Among the GI manifestations experienced by patients with COVID-19, diarrhoea (16.6%, 95% CI 12.1% to 17.3%) was still the most common symptom, followed by nausea (9.9%, 95% CI 8.2% to 11.7%). The proportion of patients experiencing loss of taste was 4.7% (95% CI 3.8% to 5.9%). The percentage of patients experiencing elevated liver enzymes was 1.9% (95% CI% 1.3% to 3.4%).

A total of 83 studies reported mortality. Of those, 82 studies reported mortality as the number of deaths at the time of the study. Only one study reported mortality as death over 30 days. 143 The overall prevalence of overall mortality and GI mortality were 23.5% (95% CI 21.2% to 26.1%) and 3.5% (95% CI 3.1% to 6.2%), respectively (online supplemental tables 6 and 7). The subgroup analysis included eight studies 19 Furthermore, three studies from Taiwan, Korea, and Japan reported zero GI mortality (table 1) .

Five studies 22 85 139 141 148 reported differences in ICU admissions among patients manifesting GI symptoms/ elevated liver enzymes and patients who did not. The total number of patients with GI symptoms/elevated liver enzymes who were admitted to the ICU was 1282, and the number of patients who did not experience GI symptoms/elevated liver enzymes and were admitted to the ICU was 2512. No statistically significant difference in Open access ICU admission rate was noted between those who experienced GI symptoms/elevated liver enzymes and those who did not. The pooled proportion was 1.01 (95% CI 0.55 to 1.83) (figure 5).

This meta-analysis of 78 798 patients with COVID-19 found that GI symptoms/elevated liver enzymes are common in patients infected with SARS-CoV-2. Subgroup analysis found that no association between the presence of GI symptoms/elevated liver enzymes and mortality or ICU admission, which is similar to the finding of other meta-analyses. 149 150 GI symptoms including abdominal pain, diarrhoea, nausea, vomiting, loss of appetite, loss of taste and elevated liver enzyme are among the presenting symptoms or laboratory abnormalities of SARS-CoV-2 infection found in this study. Diarrhoea was the most common GI symptom; this is particularly important because previous studies have shown that patients with diarrhoea on presentation have a higher stool RNA positivity and viral load than those without. 22 36 151 One study showed that 44 of 153 patients with COVID-19 tested positive for the virus in the stools. 148 In addition, a report of a patient with COVID-19 with positive faecal but negative pharyngeal and sputum viral tests has been described. 33 Moreover, a meta-analysis concluded that SARS-CoV-2 is commonly present in stool samples or anal swabs in which the virus can persist for a long period after respiratory samples become negative and that the virus may be viable. 152 This may imply that faecal oral route is a possible route of SARS-CoV-2 transmission.

The possibility of faecal oral transmission of SARS-CoV-2 emphasises the importance of frequent and proper hand hygiene. This is important in every clinical setting, but especially in low-resource areas with poor sanitation. 38 Intuitively, proper handling of the excreta of patients with COVID-19 should still be strongly enforced, and sewage from hospitals should also be properly disinfected. The presence of the virus in the digestive tract also raises the concerns of COVID-19 infection in patients with established GI conditions, as well as potential faecal microbiota transplant donors. 148 Nevertheless, the unknown effect of COVID-19 on patients with pre-existing GI diseases and its influence on treatment and outcome is a cause for concern. These implications warrant further investigation. The American Gastroenterological Association and joint society recommend the use of enhanced personal protective equipment, including the use of N95 (or N99) masks instead of surgical masks, for healthcare workers performing upper or lower GI procedures regardless of COVID-19 status. 35 It is believed that the prevalence of GI symptoms is underestimated because the majority of studies included in our study reported GI symptoms only on the day of admission but not throughout the disease course. Furthermore, many earlier studies did not report on 

other GI symptoms except for diarrhoea. 22 Based on these findings, clinicians must be aware that digestive symptoms, such as diarrhoea, may be a presenting feature of COVID-19 that can arise before respiratory symptoms and, on rare occasions, may be the only presenting manifestation of COVID-19. 33 The pooled analysis showed that the overall mortality and GI mortality were 23.5% and 3.5%, respectively. However, it is important to emphasise that reporting of COVID-19 mortality in each country varies. 153 Some countries do not depend on the availability of confirmed laboratory tests; instead, both probable and confirmed cases are used when calculating COVID-19 mortality. 154 In this meta-analysis, a subanalysis of mortality in patients with GI symptoms/elevated liver enzymes varied between countries. This difference in GI mortality can be attributed to several reasons. Differences in reporting cases, case definition, and the mortality measure used might have a great role in this geographical variation. The available mortality data mostly reported as case fatality rate, which measures the number of deaths out of all confirmed cases. 155 Furthermore, using case fatality rate is influenced by reporting and testing strategies in each country, where countries that do not have good reporting or intensive testing might miss a lot of confirmed cases and eventually overestimate mortality. 153 In addition, it is well known that comorbidities increase the risk of death from COVID-19, 154 and countries with the highest burden of chronic diseases had the highest COVID-19 mortality. Small sample size of the published GI mortality reports of some countries is another factor that can lead to inaccurate presentation of the actual GI mortality.

Our study did not show higher GI mortality among patients manifesting GI symptoms/elevated liver enzymes. However, any possible true difference in mortality may be worth further investigation among better defined patients with COVID-19 subgroups with GI symptoms/ elevated liver enzymes because one study showed that prevalence of severe disease was more common in patients who had GI symptoms than those who did not. 156 Our meta-analysis did not find a statistically significant association between patients with GI symptoms/elevated liver enzymes and ICU admission. However, to investigate such an association, it is important to consider other causes of elevated liver enzymes in patients admitted to ICU such as sepsis, hypoperfusion, hepatotoxic drugs, and parenteral nutrition. 157

Our study has several strengths. This is one of the more recent meta-analyses that summarises the literature on COVID-19 and the prevalence of overall and individual GI manifestations. 149 158-161 The large patient population and comprehensive inclusion of 158 studies allow a more precise estimation of the prevalence of GI symptoms/elevated liver enzymes associated with COVID-19. Moreover, our search included studies over 1-year period, from 1 December 2019 up to 15 December 2020, which makes it more up-to-date and more inclusive of the recent evidence. Furthermore, our meta-analysis included studies from different countries and regions.

This study, however, is subject to some limitations. Most of the studies we base our analyses on are observational, single-arm cohorts. The lack of control groups and comparison arms can lead to bias due to confounding. Additionally, regarding mortality among patients with COVID-19, most studies reported mortality at the time of the study. In other words, studies did not report mortality over a specific period of time. Furthermore, most studies reported patients with COVID-19 who have been admitted to hospital, who are more likely to have severe disease, resulting in under-representation of patients with milder disease.

In this meta-analysis, we summarise the recent reports of GI symptoms/elevated liver enzymes among patients infected with SARS-CoV-2. GI symptoms/elevated liver enzymes are commonly observed in patients with COVID-19; therefore, clinicians should be aware that diarrhoea and nausea can be the only manifestations of patients with COVID-19. Our subanalysis showed that GI mortality among patients infected with SARS-CoV-2 varied based Open access on geographical location. We also could not find a statistically significant association between ICU admission in patients with GI symptoms/elevated liver enzymes compared with those without GI symptoms/elevated liver enzymes. However, further investigation is warranted to better assess this possible association. front liners around the globe for their hard work and sacrifices made during this pandemic.

Contributors MS: study concept and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content, statistical analysis, and submission of the manuscript. FA: acquisition of data, analysis and interpretation of data, drafting of the manuscript.SS: acquisition of data and drafting of the manuscript. DA: acquisition of data and drafting of the manuscript. AB: critical revision of the manuscript for important intellectual content, statistical analysis, study supervision; he is also responsible for the overall work as a guarantor.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data generated or analysed during this study are included in this published article (and its supplementary information files).

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http:// creativecommons. org/ licenses/ by-nc/ 4. 0/.

Mohammad Shehab http:// orcid. org/ 0000-0003-2084-3956

html#:~: text= On% 20February% 2011% 2C% 202020% 2C% 20the, and% 20'D'%20for%20disease

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment

Coronavirus Disease (COVID-19) -World HealthOrganization

World Health Organization

World Health Organization

Available: https:// covid19. who. int/? gclid= CjwK CAjw iMj2 BRBF EiwA YfTbCs-zYYn g4rw UJqK D946 CSFH wJgC 2YP9 erGK VDph wwdu dJsa 3uWT xaBo CdLUQAvD_ BwE

Possible transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a public Bath

Clinical characteristics of coronavirus disease 2019 in China

It is time to address airborne transmission of COVID-19

Presumed asymptomatic carrier transmission of COVID-19

Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention

Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths

Coronavirus disease 2019 (COVID-19): a perspective from China

Clinical characteristics of 2019 novel coronavirus infection in China

Methodological index for nonrandomized studies (minors): development and validation of a new instrument

The Newcastle-Ottawa scale (NOS) for assessing the quality if nonrandomised studies in metaanalyses

Viral loads in clinical specimens and SARS manifestations

Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection

Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study

Effect of gastrointestinal symptoms in patients with COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-Infected pneumonia in Wuhan, China

The global spread of 2019-nCoV: a molecular evolutionary analysis

Who coronavirus disease (COVID-19) Dashboard, 2020. Available: covid19. who. int/? gclid= CjwK CAjw iMj2 BRBF EiwA YfTbCs-zYYn g4rw UJqK D946 CSFH wJgC 2YP9 erGK VDph wwdu dJsa 3uWT xaBo CdLUQAvD_ BwE

It is time to address airborne transmission of coronavirus disease 2019 (COVID-19)

Presumed asymptomatic carrier transmission of COVID-19

Clinical characteristics of 2019 novel coronavirus infection in China

Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses

Viral loads in clinical specimens and SARS manifestations

First case of 2019 novel coronavirus in the United States

Evidence for gastrointestinal infection of SARS-CoV-2

COVID-19 disease with positive fecal and negative pharyngeal and sputum viral tests

Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus

Joint Gi Society statement: use of personal protective equipment in Gi endoscopy

Human intestinal tract serves as an alternative infection route for middle East respiratory syndrome coronavirus

Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic Society and infectious diseases Society of America

Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and metaanalysis

Clinical features of 2019 novel coronavirus pneumonia presented gastrointestinal symptoms but without fever onset

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating personto-person transmission: a study of a family cluster

Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

A report of clinical diagnosis and treatment of nine cases of coronavirus disease 2019

Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19

High prevalence of concurrent gastrointestinal manifestations in patients with severe acute respiratory syndrome coronavirus 2: early experience from California

Epidemiology and Case Management Team, Korea Centers for Disease Control and Prevention. Early epidemiological and clinical characteristics of 28 cases of coronavirus disease in South Korea

COVID-19 National Incident Room Surveillance Team. COVID-19

Retrospective analysis of clinical features in 101 death cases with COVID

COVID-19 in solid organ transplant recipients: a single-center case series from Spain

Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support

Gastrointestinal and hepatic manifestations of 2019 novel coronavirus disease in a large cohort of infected patients from New York: clinical implications

Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes

Featuring COVID-19 cases via screening symptomatic patients with epidemiologic link during flu season in a medical center of central Taiwan

A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China

novel coronavirus disease (COVID-19) in Taiwan: reports of two cases from Wuhan

Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: a retrospective single center analysis

Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms

Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19

Diarrhea: an underestimated symptom in coronavirus disease 2019

SARS-COV2 infection in 86 healthcare workers in two Dutch hospitals in

Epidemiological and clinical characteristics of 944 cases of 2019 novel coronavirus infection of Non-COVID-19 exporting City

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

First 12 patients with coronavirus disease 2019 (COVID-19) in the United States

Olfactory and gustatory dysfunctions as a clinical presentation of mildto-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

The clinical and chest CT features associated with severe and critical COVID-19 pneumonia

Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Don't overlook digestive symptoms in patients with 2019 novel coronavirus disease (COVID-19)

Gastrointestinal Symptoms and Coronavirus Disease 2019: A Case-Control Study From the United States

Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19)

Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China

Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures

Prevalence and characteristics of gastrointestinal symptoms in patients with severe acute respiratory syndrome coronavirus 2 infection in the United States: a multicenter cohort study

Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

Clinical characteristics of 545 cases confirmed COVID-19 in Wuhan stadium cabin Hospital. available at SSRN 3552844

Lung base findings of coronavirus disease (COVID-19) on abdominal CT in patients with predominant gastrointestinal symptoms

Emerging 2019 novel coronavirus (2019-nCoV) pneumonia

First cases of coronavirus disease 2019 (COVID-19) in the who European region

The clinical characteristics of COVID-19: a retrospective analysis of 104 patients from the outbreak on board the diamond Princess cruise ship in Japan

Enteric involvement in hospitalised patients with COVID-19 outside Wuhan

The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China

Epidemiologic and clinical characteristics of 26 cases of COVID-19 arising from Patientto-Patient transmission in Liaocheng, China

Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up

Clinical characteristics of noncritically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital

Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment

Clinical characteristics of SARS-COV2 infected pneumonia with diarrhea 2020. Available at SSRN 3546120

Virological assessment of hospitalized patients with COVID-2019

Clinical characteristics of imported cases of coronavirus disease 2019 (COVID-19) in Jiangsu Province: a multicenter descriptive study

Chest CT findings in patients with coronavirus disease 2019 and its relationship with clinical features

Prolonged presence of SARS-CoV-2 viral RNA in faecal samples

Epidemiological and initial clinical characteristics of patients with family aggregation of COVID-19

Evidence for gastrointestinal infection of SARS-CoV-2

Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study

Clinical and high-resolution CT features of the COVID-19 infection: comparison of the initial and follow-up changes

Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

Clinical characteristics and outcomes of cancer patients with COVID-19

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study

Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore

A familial cluster of infection associated with the 2019 novel coronavirus indicating possible person-toperson transmission during the incubation period

Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia

A comparative study on the clinical features of coronavirus 2019 (COVID-19) pneumonia with other pneumonias

Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: a multicenter study

Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Ct features of coronavirus disease 2019 (COVID-19) pneumonia in 62 patients in Wuhan, China

SARS-CoV-2 viral load in upper respiratory specimens of infected patients

First case of 2019 novel coronavirus in the United States

SARS-CoV-2 infection presenting as colitis with chest and abdomen CT findings

COVID-19 and the gastrointestinal system: lesions beyond the symptoms?

Uncommon presentation of COVID-19: gastrointestinal bleeding

Association of digestive symptoms and hospitalization in patients with SARS-CoV-2 infection

Management of upper Gi bleeding in patients with COVID-19 pneumonia

Unusual gastrointestinal manifestations of COVID-19: two case reports

Coronavirus disease 19 with gastrointestinal symptoms as initial manifestations: a case report

Acute pancreatitis as the initial manifestation in 2 cases of COVID-19 in Wuhan

Primary presentation of COVID-19 solely with gastrointestinal symptoms: a problem for the containment of the disease

An unusual presentation of COVID-19: acute pancreatitis

The model for end-stage liver Disease-Sodium score at admission is prognostic of Covid-19 disease severity

Atypical manifestations of COVID-19 in general practice: a case of gastrointestinal symptoms

Recurrent acute pancreatitis in a patient with COVID-19 infection

Featuresof 16, 749 hospitalised UK patients with COVID-19 using the ISARIC who clinical characterization protocol

CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children -United States

Characteristics of Health Care Personnel with COVID-19 -United States

A cohort of patients with COVID-19 in a major teaching hospital in Europe

DigestiveManifestations in patients hospitalized with COVID-19

Analysis of clinical characteristics and outcomes in patients with COVID-19 based on a series of 1000 patients treated in Spanish emergency departments

Gastrointestinal involvement attenuates COVID-19 severity and mortality

Gastrointestinal involvement in COVID-19 patients: a retrospective study from a Greek COVID-19 referral hospital

COVID-19 digestive system involvement and clinical outcomes in a large academic

Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China

Acute kidney injury in SARS-CoV-2 infected patients

Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia

Gi symptoms as early signs of COVID-19 in hospitalised Italian patients

Abnormal liver tests in COVID-19: a retrospective observational cohort study of 1,827 patients in a major U.S. Hospital network

Disease course and outcomes of COVID-19 among hospitalized patients with gastrointestinal manifestations

Analysis of gastrointestinal and hepatic manifestations of SARS-CoV-2 infection in 892 patients in queens

The prevalence of gastrointestinal symptoms among patients with COVID-19 and the effect on the severity of the disease

Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan Detroit

Retrospective analysis of clinical characteristics of 405 patients with COVID-19

Gastrointestinal manifestations and associated health outcomes of COVID-19: a Brazilian experience from the largest South American public hospital

Liver injury in patients with COVID-19: clinical profiles, CT findings, the correlation of the severity with liver injury

Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19

COVID-19: faecal-oral transmission?

Prevalence and mortality of COVID-19 patients with gastrointestinal symptoms: a systematic review and meta-analysis

Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis

AGA Institute rapid review of the gastrointestinal and liver manifestations of COVID-19, meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19

Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission

Estimating mortality from COVID-19

Explaining among-country variation in COVID-19 case fatality rate

World Health Organization. Health systems response monitor (HSRM)

Association of digestive symptoms with severity and mortality of COVID-19: a protocol for systematic review and meta-analysis

Newly reported studies on the increase in gastrointestinal symptom prevalence withCOVID-19 infection: a comprehensive systematic review and meta-analysis

Gastrointestinal predictors of severe COVID-19: systematic review and meta-analysis

The prevalence of gastrointestinal symptoms, abnormal liver function, digestive system disease and liver disease in COVID-19 infection: a systematic review and meta-analysis

Gastrointestinal and hepatic abnormalities in patients with confirmed COVID-19: a systematic review and meta-analysis

Acknowledgements We acknowledge and thank all health care workers and